Solid Biosciences Inc.
www.solidbio.com
Latest From Solid Biosciences Inc.
Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
Adverse Event Concerns With Solid Biosciences' Candidate DMD Gene Therapy
The US FDA has for the second time placed a clinical hold on Solid Biosciences’ potential gene therapy for Duchenne muscular dystrophy, a move linked to a 70% decline in the company’s share price. The company had reported a serious adverse event in a patient treated with higher doses of the viral vector-delivered gene therapy.
Made In China Gene Therapy A Father's Quest To Save Son With UltraRare Condition
Patient-driven drug development meets the old saying of "where there's a will, there's a way" in China, potentially the world's largest market for rare disease treatments.
Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Solid Ventures
- Solid Biosciences LLC
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Solid Biosciences Inc.
- Senior Management
-
Ilan Ganot, CEO
Jennifer Ziolkowski, CFO
Carl Morris , PhD, CSO
Joel Schneider, PhD, CTO, Head, Exploratory R&D
Jorge A Quiroz, MD, CMO
Alvaro Amorrortu, COO - Contact Info
-
Solid Biosciences Inc.
Phone: (617) 337-4680
161 First St.
3rd Floor
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice